Premium
Neurobiological Technologies Inc (CE) (NTII)
USOTC
Hot Features
Inscrivez-vous pour des graphiques en temps réel, des outils d'analyse et des prix.
Neurobiological Technologies, Inc. (OTC Markets: NTII) (NTI or the Company) announced today that its board of directors has declared an extraordinary dividend of $0.05 per share...
Celtic Pharma Announces Initiation of Pediatric Dose Tolerance Trial Evaluating XERECEPT(R) in Pediatric Patients with Primary and Metastatic Brain Tumors PR Newswire NEW YORK, LONDON and...
Company also Announces Timing and Plans to Voluntarily Delist from the Nasdaq Capital Market and Initiate Dissolution Process EMERYVILLE, Calif., Nov. 23 /PRNewswire-FirstCall/ -- Neurobiological...
Board of Directors Declares Extraordinary Dividend of $0.75 per share EMERYVILLE, Calif., Oct. 28 /PRNewswire-FirstCall/ -- Neurobiological Technologies, Inc. (NASDAQ:NTII) ("NTI") announced...
EMERYVILLE, Calif., Oct. 19 /PRNewswire-FirstCall/ -- Neurobiological Technologies, Inc. (NASDAQ:NTII) ("NTI") announced today it has submitted written notice to the NASDAQ Stock Market LLC...
EMERYVILLE, Calif., Sept. 17 /PRNewswire-FirstCall/ -- Neurobiological Technologies, Inc. (NASDAQ:NTII) ("NTI") announced today that, on September 15, 2009, it received a letter from The Nasdaq...
EMERYVILLE, Calif., Sept. 19 /PRNewswire-FirstCall/ -- Neurobiological Technologies, Inc. announced today that its financial statements for the fiscal year ended June 30, 2007, included in the...
Scimitar Equity Research Issues Q3/05 Review of Neurobiological Technologies, Inc. BOSTON, May 11 /PRNewswire-FirstCall/ -- Scimitar Equity Research, Inc. (Scimitar) issues a review of...
Scimitar Equity Research Issues Review of Neurobiological Technologies, Inc. BOSTON, Aug. 20 /PRNewswire/ -- Scimitar Equity Research, Inc. (Scimitar) issued a review of Neurobiological...
Conference Call Alert - Neurobiological Technologies, Inc. (Nasdaq: NTII) RICHMOND, Calif., April 21 /PRNewswire-FirstCall/ -- Please join us for an in-depth update regarding the initiation of...
| Période | Variation | Variation % | Ouver. | Haut | Bas | Moyenne Vol. Quot. | VWAP | |
|---|---|---|---|---|---|---|---|---|
| 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
| 4 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
| 12 | 0 | 0 | 0.0001 | 0.0001 | 0.0001 | 0 | 0 | CS |
| 26 | 0 | 0 | 0.0001 | 0.0001 | 0.0001 | 636148 | 0.0001 | CS |
| 52 | 9.9E-5 | 9900 | 1.0E-6 | 0.0001 | 1.0E-6 | 295570 | 9.57E-5 | CS |
| 156 | -0.0079 | -98.75 | 0.008 | 0.008 | 1.0E-6 | 122594 | 9.529E-5 | CS |
| 260 | -0.0042 | -97.6744186047 | 0.0043 | 0.03 | 1.0E-6 | 52984 | 0.00380807 | CS |
| Aucune Discussion Trouvée |
| Ajouter une Discussion |
Les dernières valeurs consultées apparaîtront dans cette boîte, vous permettant de choisir facilement les titres vus auparavant.
Assistance: support@advfn.fr
En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales
